CD8A and neoplasm: High percentages of PD-1+ CD8 T cells were identified in group 3 MB tumors; therefore, in vivo blockade of PD-1 expressing lymphocyte population showed significant anti-tumor effects group 3 MB-bearing animals, which did not work for SHH-MB animals.